论文部分内容阅读
目的观察替比夫定治疗HBV DNA和HBeAg阴性慢性乙型肝炎效果。方法运用彩色多普勒超声仪检测53例HBV DNA和HBeAg阴性慢性乙型肝炎患者及42例未使用替比夫定治疗的HBV DNA和HBeAg阴性患者门静脉主干最大截面直径、平均流速、流量、肝静脉频谱及肝脏表面,同时检测肝纤维化指标及生化指标,并作HBsAg定量检测。结果替比夫定治疗组患者治疗后门静脉内径较治疗前减小(Dpv),门静脉血流速度增加(Vpv),血流量减少(Qpv)(P<0.01);肝静脉频谱、肝脏表面光滑度与对照组比较显著改善(P<0.01),HA、PⅢ、PALT、TBil及HBsAg含量显著降低(P<0.01)。结论替比夫定治疗HBV DNA和HBeAg阴性慢性乙型肝炎可显著改善患者的肝脏组织学及预后。
Objective To observe the effect of telbivudine in the treatment of HBV DNA and HBeAg-negative chronic hepatitis B. Methods Fifty-three patients with HBV DNA and HBeAg-negative chronic hepatitis B and 42 patients with HBV DNA and HBeAg-negative patients without telbivudine were examined by color Doppler flow imaging. The maximum cross-sectional diameter, average velocity, flow rate, Venous spectrum and liver surface, at the same time detection of liver fibrosis indicators and biochemical indicators, and HBsAg quantitative detection. Results After telbivudine treatment, the diameter of portal vein was decreased (Dpv), portal vein velocity (Vpv), blood flow decreased (Qpv) (P <0.01); hepatic vein frequency spectrum, liver surface smoothness Compared with the control group, the levels of HA, PⅢ, PALT, TBil and HBsAg were significantly decreased (P <0.01). Conclusion Telbivudine treatment of HBV DNA and HBeAg-negative chronic hepatitis B can significantly improve the patient’s liver histology and prognosis.